Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxiaStephanie G. Craig, Manuel Salto‐Tellez, Andrew Blake et al.|British Journal of Cancer|2020Cited by 63
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utilityMuhammad A. Alvi, Manuel Salto‐Tellez, Darragh G. McArt et al.|Oncotarget|2015Cited by 55
Evolutionary genetic algorithm identifies <i>IL2RB</i> as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancerMatthew Alderdice, Darragh G. McArt, Stephanie G. Craig et al.|NAR Genomics and Bioinformatics|2021Cited by 22
<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancerPhilip D. Dunne, Mark Lawler, Helen G. Coleman et al.|Oncotarget|2018Cited by 11
<i>Bcl-xL</i> as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in <i>BRAF</i> -mutant stage II and III colon cancerPhilip D. Dunne, Mark Lawler, Helen G. Coleman et al.|bioRxiv (Cold Spring Harbor Laboratory)|2017Cited by 1